How to Get Trulicity (Dulaglutide) in Wisconsin

Who Can Prescribe Trulicity in Wisconsin

Any Wisconsin-licensed physician (MD or DO), nurse practitioner with prescriptive authority, or physician assistant operating under a collaborative agreement can write a dulaglutide prescription. Wisconsin Statute § 441.16 grants advanced practice nurse prescribers (APNPs) independent prescriptive authority for legend drugs, including GLP-1 receptor agonists. PAs prescribe under the supervisory framework in § 448.9726.

Endocrinologists and diabetologists are the most common prescribers, but primary care providers initiate dulaglutide frequently. The American Diabetes Association (ADA) 2024 Standards of Care recommend a GLP-1 receptor agonist as second-line therapy after metformin for patients with established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk. In the REWIND trial (N=9,901), dulaglutide 1.5 mg reduced the composite of major adverse cardiovascular events (MACE) by 12% versus placebo over a median 5.4 years (HR 0.88, 95% CI 0.79 to 0.99). That cardiovascular indication expanded the pool of prescribers interested in dulaglutide beyond endocrinology into cardiology and internal medicine.

If your current provider does not prescribe GLP-1 agents, ask for a referral to an endocrinologist or a diabetes-focused telehealth service that holds a Wisconsin license.

Telehealth Prescribing for Trulicity in Wisconsin

Wisconsin law allows telehealth prescribing of Trulicity. The state updated its telehealth parity provisions under § 256.35 and subsequent emergency orders during 2020, and those flexibilities have been made permanent through administrative rulemaking. A provider licensed in Wisconsin (or holding an interstate compact license) can evaluate a patient via synchronous audio-video visit and prescribe dulaglutide without requiring a prior in-person encounter.

Telehealth visits for dulaglutide typically involve a review of HbA1c, fasting glucose, renal function (eGFR), and a personal or family history of medullary thyroid carcinoma (MTC). The FDA-approved prescribing information for Trulicity includes a boxed warning regarding thyroid C-cell tumors observed in rodents, so prescribers must screen for MEN2 syndrome or a personal history of MTC before initiating therapy [1]. Telehealth platforms operating in Wisconsin can order lab work through Quest, Labcorp, or local hospital systems, with results typically available within 48 hours.

A synchronous video visit generally runs 15 to 25 minutes. Many platforms allow same-day or next-day scheduling, which compresses the timeline from clinical decision to pharmacy fill compared with traditional in-office wait times that average 20.5 days for new endocrinology referrals nationwide according to a 2022 Merritt Hawkins survey.

Labs Required Before Starting Dulaglutide

Prescribers in Wisconsin follow ADA Standards of Care when evaluating candidates for dulaglutide. The standard pre-prescribing workup includes:

• HbA1c: confirms glycemic status and establishes a baseline. Most insurers require an HbA1c of 7.0% or higher for PA approval.
• Fasting blood glucose: supports the HbA1c finding.
• Comprehensive metabolic panel (CMP): checks renal function via eGFR and hepatic enzymes. Dulaglutide requires no dose adjustment for mild-to-moderate renal impairment per the FDA label, but monitoring is recommended [2].
• Lipid panel: documents baseline cardiovascular risk markers; REWIND showed dulaglutide modestly improved total cholesterol and LDL [3].
• Thyroid history screening: a personal or family history of MTC or MEN2 is a contraindication per the Endocrine Society clinical guidance.

Some insurers, including Wisconsin Medicaid (BadgerCare Plus), also require documentation that the patient has tried and failed metformin for at least 90 days before authorizing dulaglutide. Obtain labs through your telehealth platform's lab partner or any in-network draw station. Results from labs taken within the prior 90 days are generally accepted.

Wisconsin Medicaid (BadgerCare Plus) Coverage

Wisconsin Medicaid covers dulaglutide for type 2 diabetes with prior authorization. The program, administered through managed care organizations (MCOs) such as Quartz, Molina, and Dean Health Plan, requires prescribers to demonstrate ADA guideline-concordant prescribing, including a trial of metformin (or documented contraindication) and a current HbA1c at or above target. The PA request must include:

1. Diagnosis of type 2 diabetes with ICD-10 code (E11.x).
2. Most recent HbA1c value and date of test.
3. Documentation of metformin trial (dose, duration, reason for inadequacy or intolerance).
4. Prescriber attestation that the patient does not have a personal or family history of MTC or MEN2.
5. Requested dose and duration (initial: 0.75 mg weekly; maintenance: up to 4.5 mg weekly per FDA dosing).

PA turnaround in Wisconsin MCOs averages 48 to 72 hours for standard requests and 24 hours for urgent requests. Denials can be appealed through the MCO's internal grievance process or escalated to the Wisconsin Department of Health Services.

Commercial Insurance and Prior Authorization

Most commercial plans in Wisconsin (Anthem, UnitedHealthcare, Quartz, Group Health Cooperative) place dulaglutide on formulary tier 3 (preferred brand) or tier 4 (non-preferred brand). A 2023 analysis published in Diabetes Care found that 89% of commercial plans required prior authorization for GLP-1 receptor agonists. The PA documentation mirrors Medicaid requirements: confirmed T2D diagnosis, HbA1c, metformin trial, and thyroid screening.

Step therapy rules vary. Some Wisconsin plans require a trial of a sulfonylurea or SGLT2 inhibitor before approving dulaglutide. The REWIND trial's cardiovascular outcome data [4] and the ADA/EASD consensus statement provide clinical justification for bypassing step therapy in patients with ASCVD or multiple cardiovascular risk factors. Your prescriber can cite these documents in a letter of medical necessity.

Copays for commercially insured patients in Wisconsin range from $25 (with the Eli Lilly Trulicity Savings Card) to $150 per month without manufacturer support. The Savings Card covers eligible patients for up to 24 months and is not valid for government-funded insurance programs.

Filling Your Trulicity Prescription at Wisconsin Pharmacies

Once PA is approved, dulaglutide can be filled at any Wisconsin retail pharmacy. Large chains (Walgreens, CVS, Walmart) and Wisconsin-based independents stock Trulicity pens. Specialty pharmacies may be required by certain insurance plans, particularly for mail-order delivery. Common specialty pharmacy networks in Wisconsin include Optum Specialty, CVS Specialty, and Accredo.

Dulaglutide must be stored at 2°C to 8°C (36°F to 46°F) until use. A single pen can remain at room temperature (up to 30°C / 86°F) for 14 days per the FDA storage guidance. For mail-order delivery, pharmacies ship with cold packs and insulated packaging. Wisconsin residents in rural areas (northern counties such as Ashland, Bayfield, or Iron) may find mail-order more practical than a 60-plus mile drive to a stocking pharmacy.

503A-licensed compounding pharmacies in Wisconsin operate under FDA Section 503A and may compound patient-specific prescriptions, but dulaglutide as a branded biologic is not typically compounded. Compounded GLP-1 receptor agonist formulations (such as compounded semaglutide) are a separate regulatory category and should not be confused with brand Trulicity.

Timeline from Prescription to First Injection

The total time from initial consultation to injecting your first Trulicity dose in Wisconsin depends on three variables: appointment availability, lab processing, and PA turnaround.

Telehealth pathway (fastest): Same-day or next-day consultation, labs drawn within 24 to 48 hours, PA submitted on day 2 to 3, PA approved by day 4 to 5, pharmacy fill on day 5 to 7. Total: roughly 5 to 7 business days.

In-person endocrinology referral (slowest): New patient wait averages 20 to 34 days per specialty in Wisconsin according to AAMC workforce data. Add 3 to 5 days for PA processing. Total: 25 to 40 days.

The gap is significant. Telehealth compresses access by removing the referral bottleneck. For patients whose HbA1c is above 9%, the ADA recommends initiating combination injectable therapy promptly. Delays of a month or more carry real glycemic cost.

Transferring a Trulicity Prescription to Wisconsin

Wisconsin accepts prescription transfers from any U.S. State under standard pharmacy transfer law. Your originating pharmacy calls or electronically transmits the prescription to your new Wisconsin pharmacy. If the transfer includes remaining refills, those refills carry over. PA approvals, however, are insurer-specific and do not automatically transfer when you change health plans.

If you move to Wisconsin and switch from an out-of-state Medicaid plan to BadgerCare Plus, you will need a new PA. Keep copies of your lab work, prescription history, and any PA approval letters. Presenting these to a new Wisconsin prescriber speeds the re-authorization process. The CMS continuity of care requirements mandate that Medicaid MCOs provide a temporary supply (usually 30 days) during transitions for established therapies.

Cost-Reduction Strategies for Wisconsin Patients

Dulaglutide's wholesale acquisition cost (WAC) is approximately $1,000 per month for the 1.5 mg dose. Actual out-of-pocket costs vary widely. These are the primary strategies Wisconsin patients use to lower their spend:

Eli Lilly Savings Card. Commercially insured patients may pay as little as $25 per monthly fill. Not valid for Medicare, Medicaid, or Tricare beneficiaries. Savings may apply for up to 24 months per Eli Lilly's patient assistance programs.

Lilly Cares Foundation. Uninsured patients or those with financial hardship may qualify for free Trulicity through Eli Lilly's patient assistance program. Household income must generally fall below 400% of the federal poverty level.

Medicare Part D. Wisconsin Medicare beneficiaries pay coinsurance rates that vary by plan and coverage phase. Under the Inflation Reduction Act (IRA), the annual Part D out-of-pocket cap is $2,000 starting in 2025, which benefits patients on high-cost injectables like dulaglutide [5].

State pharmaceutical assistance. Wisconsin's SeniorCare program provides prescription drug assistance for residents aged 65 and older with income at or below 240% of the federal poverty level. Enrollment information is available through the Wisconsin Department of Health Services.

Dulaglutide Dosing and Titration in Wisconsin Practice

The standard starting dose is 0.75 mg subcutaneously once weekly. After at least 4 weeks, the dose may increase to 1.5 mg weekly if additional glycemic control is needed. The FDA expanded the approved dose range to include 3.0 mg and 4.5 mg strengths for patients requiring intensification [6]. In the AWARD-11 trial (N=1,842), dulaglutide 4.5 mg reduced HbA1c by 1.87% at 36 weeks versus 1.54% for 1.5 mg, with a similar safety profile.

Wisconsin prescribers typically titrate at 4-week intervals: 0.75 mg for 4 weeks, then 1.5 mg for 4 weeks, then 3.0 mg, then 4.5 mg if the HbA1c target is not reached. Gastrointestinal side effects (nausea, diarrhea, vomiting) are most common during titration. In the REWIND trial, nausea occurred in 15.4% of dulaglutide-treated patients versus 7.1% on placebo, but discontinuation due to GI adverse events was low at 4.3% [7].

Injection sites include the abdomen, thigh, or upper arm. Rotate sites weekly. The single-dose pen does not require reconstitution. Patients should allow the pen to reach room temperature for 15 minutes before injecting.

Monitoring After Starting Trulicity

Follow-up after initiation typically includes an HbA1c check at 3 months and then every 3 to 6 months per ADA monitoring recommendations. Wisconsin telehealth platforms and in-person clinics both order these labs routinely. Additional monitoring includes:

• Renal function: annual eGFR for patients with baseline CKD or risk factors. A post hoc analysis of REWIND showed dulaglutide reduced the composite renal outcome (new macroalbuminuria, sustained eGFR decline of 30% or more, or chronic renal replacement therapy) by 15% versus placebo (HR 0.85, 95% CI 0.77 to 0.93) [8].
• Lipid panel: at baseline and 6 to 12 months. Dulaglutide may modestly lower LDL and triglycerides per REWIND secondary analyses.
• Pancreatitis symptoms: while no causal link has been established, the FDA label advises monitoring for persistent severe abdominal pain.
• Weight: mean weight loss in REWIND was 2.9 kg more than placebo at 5 years. The AWARD trials showed a range of 1.5 to 4.6 kg weight reduction depending on comparator and dose [9].

Report any symptoms of pancreatitis, severe GI distress, or hypoglycemia (particularly if taking concurrent sulfonylureas or insulin) to your prescriber immediately.

Dulaglutide 1.5 mg once weekly reduced HbA1c by a mean of 1.1% at 5.4 years in the REWIND population, with sustained glycemic benefit and no increase in severe hypoglycemia versus placebo according to Gerstein et al., Lancet 2019.